Marshall Wace
ALNY icon

Marshall Wace’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marshall Wace’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2M Sell
259,799
-839,519
-76% -$253M 0.06% 256
2026
Q1 		$364M Buy
1,099,318
+549,396
+100% +$187M 0.36% 31
2025
Q4 		$219M Buy
549,922
+41,551
+8% +$18.4M 0.2% 77
2025
Q3 		$232M Buy
508,371
+269,798
+113% +$110M 0.24% 62
2025
Q2 		$77.8M Sell
238,573
-30,359
-11% -$8.4M 0.09% 218
2025
Q1 		$72.6M Sell
268,932
-109,717
-29% -$28.2M 0.09% 187
2024
Q4 		$89.1M Buy
378,649
+315,182
+497% +$82.9M 0.11% 174
2024
Q3 		$17.5M Buy
+63,467
New +$16.5M 0.02% 558
2024
Q1 		– Sell
-1,300
Closed -$249K – 2403
2023
Q4 		$249K Buy
+1,300
New +$221K ﹤0.01% 1925
2023
Q3 		– Sell
-11,085
Closed -$2.11M – 2152
2023
Q2 		$2.11M Buy
+11,085
New +$2.2M ﹤0.01% 1382
2022
Q3 		– Sell
-165,292
Closed -$24.1M – 3297
2022
Q2 		$24.1M Buy
+165,292
New +$23.4M 0.05% 389
2021
Q4 		– Sell
-16,427
Closed -$3.1M – 3826
2021
Q3 		$3.1M Buy
+16,427
New +$3.08M 0.01% 1237
2020
Q3 		– Sell
-58,231
Closed -$8.63M – 1547
2020
Q2 		$8.63M Buy
+58,231
New +$7.85M 0.06% 324
2019
Q3 		– Sell
-234,539
Closed -$17M – 1652
2019
Q2 		$17M Buy
+234,539
New +$18M 0.14% 161
2016
Q3 		– Sell
-34,727
Closed -$1.93M – 930
2016
Q2 		$1.93M Buy
+34,727
New +$2.19M 0.02% 597
2014
Q3 		– Sell
-5,000
Closed -$316K – 861
2014
Q2 		$316K Buy
+5,000
New +$297K ﹤0.01% 749

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's ALNY Position: Q2 2026 in Review

Marshall Wace reduced its Alnylam Pharmaceuticals (ALNY) stake by 76% in Q2 2026, selling an estimated $253M and leaving 259,799 shares worth $78.2M. The position accounts for 0.06% of the portfolio, ranked #256.

Marshall Wace first reported a position in ALNY in Q2 2014 and has held it in 16 quarters since. The position peaked at $364M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Marshall Wace held 259,799 shares of Alnylam Pharmaceuticals worth $78.2M as of Q2 2026.
  • Marshall Wace sold 839,519 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $253M.
  • Alnylam Pharmaceuticals made up 0.06% of Marshall Wace's portfolio in Q2 2026, its #256 holding.
  • Marshall Wace first reported a position in Alnylam Pharmaceuticals in Q2 2014 and has held it in 16 quarters since.
  • Marshall Wace's Alnylam Pharmaceuticals position peaked at $364M in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.